This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
Sugemalimab — Description, Dosage, Side Effects | PillsCard
Rx
Sugemalimab
600 mg (30 mg/ml), Koncentrat do sporządzania roztworu do infuzji
INN: Sugemalimabum
Data updated: 2026-04-13
Available in:
🇨🇿🇩🇪🇬🇧🇵🇱🇵🇹🇸🇰
Form
Koncentrat do sporządzania roztworu do infuzji
Dosage
600 mg (30 mg/ml)
Route
dożylna
Storage
—
About This Product
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
Manufacturer
CStone Pharmaceuticals Ireland Limited (Holandia)
Composition
Sugemalimabum 600 mg
ATC Code
L01FF11
Source
URPL
It is a fully human monoclonal antibody directed against the immunosuppressive ligand, programmed cell death ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential antineoplastic and immune checkpoint inhibitory activity.
Following administration, sugemalimab targets and specifically binds to PD-L1, blocking its binding to and activation of its receptor, programmed cell death protein 1 (PD-1).
This reverses the inactivation of T cells caused by PD-1/PD-L1 signalling and enhances the cytotoxic T lymphocyte (CTL)-mediated antitumour immune response against tumour cells expressing PD-L1.
PD-L1 is overexpressed by many types of human cancer cells.
The binding of PD-L1 to PD-1 on T cells suppresses the immune system and results in immune evasion.
PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T cells.
The anti-PD-L1 monoclonal antibody CS1001 mirrors natural immunoglobulin G4 (IgG4), potentially reducing immunogenicity and other toxicities.
⚠️ Warnings
Pregnancy
Pregnancy:
The use of sugemalimab is not recommended during pregnancy.
Breast-feeding
Breast-feeding:
A decision must be made whether to discontinue breast-feeding or to discontinue treatment with sugemalimab, taking into account the benefit of breast-feeding for the child and the benefit of sugemalimab therapy for the woman.
Driving
Driving:
Patients experiencing fatigue should be advised not to drive or operate machinery until symptoms have resolved.
Talk to your doctor or nurse before you are given this medicine if:
• you have an autoimmune disease (a condition in which the body attacks its own cells)
• you have received a live virus vaccine within 28 days prior to starting treatment
• you have a history of a lung disease called interstitial lung disease or idiopathic pulmonary fibrosis
• you have or have had a chronic viral liver infection, including hepatitis B (HBV) or hepatitis C (HCV)
• you have human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)
• you have liver damage
• you have kidney damage
When you are given this medicine, you may experience some serious side effects. These side effects may sometimes become life-threatening and may lead to death. They may occur at any time during treatment or even weeks or months after your treatment has ended:
• This medicine may cause infusion-related reactions (such as sudden severe swelling of the face/throat/limbs or anaphylaxis).
This medicine acts on the immune system and may cause inflammation in parts of your body. The inflammation may cause serious damage to your body and some inflammatory conditions may be life-threatening and require treatment or discontinuation of treatment. These reactions may involve one or more organ systems. This may result in inflammation and loss of function of the lungs, stomach or intestines, skin, liver, kidneys, heart muscle, other muscles or hormonal glands.
Tell your doctor or nurse if you are taking, have recently taken or might take immunosuppressive treatment or other medicines.
This includes medicines obtained without a prescription, including herbal medicines.
